ESMO Virtual Congress 2020 Bladder Cancer - Results from #20

Viewing 21-34 of 34 articles

ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study of the First-Line Durvalumab with or without Tremelimumab vs. Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial Carcinoma (DANUBE)

ESMO Virtual Congress 2020: Patient-Reported Outcomes from IMvigor130: Atezolizumab + Platinum-Based Chemotherapy vs placebo + PBC in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitors

ESMO Virtual Congress 2020: Pembrolizumab Combined with Chemotherapy vs Chemotherapy Alone as First-Line Therapy for Advanced Urothelial Carcinoma: KEYNOTE-361

ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial Carcinoma

ESMO Virtual Congress 2020: The KEYNOTE-361 Trial and the DANUBE Trial - Invited Discussant

ESMO Virtual Congress 2020: Erdafitinib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Subgroup Analyses of Long-Term Efficacy Outcomes of a Pivotal Phase 2 Trial (BLC2001)

ESMO Virtual Congress 2020: Patient-Reported Outcomes from JAVELIN Bladder 100: Avelumab First-Line Maintenance Plus Best Supportive Care vs Best Supportive Care Alone For Advanced Urothelial Carcinoma

ESMO Virtual Congress 2020: What is the Future of Immunotherapy in Urothelial Cancer?

ESMO Virtual Congress 2020: Sitravatinib in Combination with Nivolumab Clinical Activity in Checkpoint Inhibitor Naïve, Platinum-Experienced Patients with Advanced or Metastatic Urothelial Carcinoma

ESMO Virtual Congress 2020: BGB-A333, an Anti-PD-L1 Monoclonal Antibody, in Combination with Tislelizumab in Patients with Urothelial Carcinoma

ESMO Virtual Congress 2020: Subgroup Analyses from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + Best Supportive Care (BSC) vs BSC Alone with 1L Chemotherapy for Advanced Urothelial Carcinoma

ESMO Virtual Congress 2020: Long-Term Results of Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Urothelial Cancer in the EV-201 Study in Patients Previously Treated with Platinum and PD-1/PD-L1 Inhibitors

ESMO Virtual Congress 2020: EV-201: Long-Term Results of Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Platinum and PD-1/PD-L1 Inhibitors

1
2